- Home
- LCFY vs HSCS Comparison
LCFY vs HSCS Comparison
Compare LCFY & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCFY | HSCS |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | Australia | United States |
| Employees | 18 | 12 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LCFY | HSCS |
|---|---|---|
| Price | $4.22 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 13.6K | 8.1K |
| Earning Date | 03-13-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,072.41 |
| Revenue Next Year | N/A | $2,700.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.50 | $2.01 |
| 52 Week High | $13.98 | $6.47 |
Technical Indicators
Market Signals| Indicator | LCFY | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 43.53 |
| Support Level | $4.07 | $2.09 |
| Resistance Level | $4.80 | $2.79 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 39.05 | 50.00 |
Price Performance
Historical ComparisonAbout LCFY Locafy Limited
Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.